Biocryst Pharmaceuticals (BCRX) Net Margin (2010 - 2026)
Biocryst Pharmaceuticals (BCRX) reported Net Margin of 461.48% for Q1 2026, down 46150.0% on a YoY basis from N/an in Q1 2025, and down 101.33% quarter-over-quarter from 34723.87% in Q4 2025.
Biocryst Pharmaceuticals (BCRX) Net Margin (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals has reported Net Margin for 17 years, with the latest figure at 461.48% in Q1 2026.
- For the quarter ending Q1 2026, Net Margin fell 46150.0% year-over-year to 461.48%; the trailing twelve-month figure through Mar 2026 stood at 95.44% (down 8482.0% YoY), and the FY2025 full-year result was 30.16%, up 4988.0% from the prior year.
- Net Margin for Q1 2026 stood at 461.48%, down from 34723.87% in the prior quarter.
- The five-year high for Net Margin was 34723.87% in Q4 2025, with the low at 461.48% in Q1 2026.
- Historically, Net Margin has averaged 1972.38% across 5 years, with a median of 41.67% in 2023.
- Annual changes were most pronounced in 2025 — Net Margin soared 3474424 bps — and 2026, when it slumped 46150 bps.
- Biocryst Pharmaceuticals' Net Margin stood at 89.94% in 2022, then increased by 27 bps to 66.09% in 2023, then jumped by 69 bps to 20.37% in 2024, then soared by 170556 bps to 34723.87% in 2025, then plunged by 101 bps to 461.48% in 2026.
- The last three Net Margin figures came in at 461.48% (Q1 2026), 34723.87% (Q4 2025), and 8.09% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 9.19% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 26.57% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 35.18% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 2.94% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 24.30% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 4.16% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -168.42% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -15.15% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 31.38% |
| 10 | Biocryst Pharmaceuticals | 2.02 Bn | 1.78 Bn | 151.04 Mn | -461.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -461.48% |
| Dec 31, 2025 | 34,723.87% |
| Sep 30, 2025 | 8.09% |
| Jun 30, 2025 | 3.11% |
| Mar 31, 2025 | 0.02% |
| Dec 31, 2024 | -20.37% |
| Sep 30, 2024 | -11.99% |
| Jun 30, 2024 | -11.59% |
| Mar 31, 2024 | -38.14% |
| Dec 31, 2023 | -66.09% |
| Sep 30, 2023 | -41.67% |
| Jun 30, 2023 | -91.31% |
| Mar 31, 2023 | -77.54% |
| Dec 31, 2022 | -89.94% |
| Sep 30, 2022 | -56.08% |
| Jun 30, 2022 | -89.82% |
| Mar 31, 2022 | -148.62% |
| Dec 31, 2021 | -37.70% |
| Sep 30, 2021 | -143.44% |
| Jun 30, 2021 | -86.47% |